What is semaglutide?

Semaglutide is a GLP-1 receptor agonist, a medication that mimics a natural hormone called glucagon-like peptide-1 (GLP-1). Your body produces GLP-1 in the gut after eating. It signals fullness to the brain, slows digestion, and helps regulate blood sugar. Semaglutide is an engineered version of this hormone, modified to last much longer in the body, about seven days instead of a few minutes.

It was originally developed by Novo Nordisk for type 2 diabetes and approved by the FDA as Ozempic in 2017. In June 2021, a higher-dose formulation was approved specifically for chronic weight management under the brand name Wegovy. In 2024, an oral formulation was also approved.

How it works

Semaglutide works through three primary mechanisms:

1. Appetite suppression

GLP-1 receptors are concentrated in the hypothalamus, the brain region that regulates hunger and satiety. Semaglutide activates these receptors, reducing hunger signals and increasing feelings of fullness. Most patients describe it as a fundamental shift in their relationship with food: cravings diminish, portion sizes naturally decrease, and the constant mental noise around eating quiets down.

2. Slowed gastric emptying

Semaglutide delays how quickly food leaves your stomach. This means you feel full longer after meals. It's not uncomfortable, you simply don't feel hungry as quickly. This is also why the most common side effects are gastrointestinal: the slower transit gives some people nausea, especially early on.

3. Improved insulin signaling

Semaglutide enhances glucose-dependent insulin secretion, meaning it helps your body manage blood sugar more effectively, but only when blood sugar is elevated (reducing the risk of hypoglycemia). It also reduces glucagon secretion, which further stabilizes blood sugar. This is why it was first developed for diabetes, and why patients on semaglutide often see improvements in metabolic markers even before significant weight is lost.

The clinical evidence

Semaglutide has one of the most robust evidence bases of any weight loss medication. The landmark STEP trial program, a series of large, randomized, placebo-controlled trials, established its efficacy across diverse populations.

In practical terms, a 220-pound person could expect to lose approximately 30-35 pounds over the first year. Some patients lose significantly more.

The SELECT trial also demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese adults, making semaglutide the first obesity medication to show cardiovascular benefit.

Dosing schedule

Semaglutide is administered as a once-weekly subcutaneous injection, a small needle injected into the abdomen, thigh, or upper arm. The dose is gradually increased (titrated) over 16-20 weeks to minimize side effects:

  1. Weeks 1-4: 0.25 mg/week (initiation dose, primarily for tolerability)
  2. Weeks 5-8: 0.5 mg/week
  3. Weeks 9-12: 1.0 mg/week
  4. Weeks 13-16: 1.7 mg/week
  5. Week 17+: 2.4 mg/week (maintenance dose)

Some patients achieve their goals at lower doses and don't need to reach 2.4 mg. Your provider will adjust based on your response and tolerability.

Side effects

The most common side effects are gastrointestinal, and they typically occur during the dose-titration phase:

Most side effects are dose-dependent and improve as the body adjusts. The slow titration schedule exists specifically to minimize them. Serious side effects, pancreatitis, gallbladder disease, thyroid C-cell tumors (seen in rodent studies but not confirmed in humans), are rare but should be discussed with your provider.

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Who is a candidate?

Semaglutide for weight management is generally indicated for adults with:

It's not appropriate for people who are pregnant, breastfeeding, or have certain medical conditions. A licensed provider will evaluate your health history, current medications, and goals before prescribing.

What to expect: month by month

Month 1 (0.25-0.5 mg)

Appetite begins to decrease. You may notice you're thinking about food less. Some nausea is common, especially in the first week or two. Weight loss is typically 2-5 pounds, largely from reduced caloric intake as appetite diminishes.

Months 2-3 (0.5-1.0 mg)

Appetite suppression becomes more pronounced. Most patients lose 5-10% of their starting weight by month 3. Food noise, the constant background thinking about meals and snacks, often disappears entirely. Nausea usually subsides by this point.

Months 4-6 (1.0-2.4 mg)

Dose reaches or approaches maintenance level. Weight loss continues at a steady pace of 1-2 pounds per week. Patients often report improvements in energy, sleep quality, and blood pressure. Lab markers (A1c, lipids, inflammatory markers) begin to improve.

Months 6-12 (2.4 mg maintenance)

Most of the total weight loss occurs during this window. Average loss at one year is 15% of starting body weight. Body composition shifts, not just fat loss, but reduced visceral fat around organs. Cardiovascular risk markers continue to improve.

Beyond 12 months

Long-term data (STEP 5, 2 years) shows weight loss is maintained as long as treatment continues. Discontinuation typically leads to weight regain, this is a chronic condition requiring ongoing management, not a short-term fix. Your provider will work with you on a sustainable long-term plan.

The bottom line

Semaglutide represents a genuine paradigm shift in obesity medicine. It's not a magic bullet, it works best alongside healthy eating and movement, but it addresses the biological drivers of weight gain that willpower alone cannot overcome. For the right candidate, it's one of the most effective tools available.